PE20010962A1 - Derivados de heterociclo-alquilsulfonil-pirazol como agentes anti-inflamatorios/analgesicos - Google Patents
Derivados de heterociclo-alquilsulfonil-pirazol como agentes anti-inflamatorios/analgesicosInfo
- Publication number
- PE20010962A1 PE20010962A1 PE2000001289A PE0012892000A PE20010962A1 PE 20010962 A1 PE20010962 A1 PE 20010962A1 PE 2000001289 A PE2000001289 A PE 2000001289A PE 0012892000 A PE0012892000 A PE 0012892000A PE 20010962 A1 PE20010962 A1 PE 20010962A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- heterocycle
- halogen
- derivatives
- alkylsulfonil
- Prior art date
Links
- 239000000730 antalgic agent Substances 0.000 title 1
- 239000002260 anti-inflammatory agent Substances 0.000 title 1
- 230000003110 anti-inflammatory effect Effects 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 2
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 abstract 2
- -1 4-BROMO-PHENYL Chemical class 0.000 abstract 1
- 102000010907 Cyclooxygenase 2 Human genes 0.000 abstract 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 150000003180 prostaglandins Chemical class 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Pregnancy & Childbirth (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Obesity (AREA)
Abstract
SE REFIERE A DERIVADOS DE HETEROCICLO ALQUIL SULFONIL PIRAZOL DE FORMULA I DONDE A ES UN GRUPO A1, A2, A3, ENTRE OTROS; m ES 0-2; X ES CR8, N; R2 ES H, HALOGENO, ALQUILO C1-C6, ENTRE OTROS; R3 ES H, ALQUILO C1-C6, ALQUENILO C2-C6; ENTRE OTROS; R4 ES ALQUILO C1-C6 SUSTITUIDO CON HALOGENO; R5 ES H, HALOGENO, OH, MERCAPTO, ALQUILO C1-C6, ENTRE OTROS; R6 ES FENILO, FENILO CONDENSADO CON HETEROCICLO; CARBOCICLO DE 5-7 MIEMBROS, HETEROCICLO; R7 ES H, ALQUILO C1-C6; R8 ES H, HALOGENO, OH, MERCAPTO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS 2-[5-(4-BROMO-FENIL)-3-TRIFLUOROMETIL-PIRAZOL-1-IL]-5-METANOSULFONIL-PIRIDINA, 5-HIDRAZINO-2-(METILSULFONIL)PIRIDINA, ENTRE OTROS. TAMBIEN SE REFIERE A COMPUESTOS DE FORMULA V". EL COMPUESTO I ES INHIBIDOR DE LA BIOSINTESIS DE PROSTAGLANDINAS POR LO QUE PUEDE SER UTIL PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR CICLOOXIGENASA 2 COMO ARTRITIS, NEURODEGENERACION, CANCER DE COLON
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16870199P | 1999-12-03 | 1999-12-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20010962A1 true PE20010962A1 (es) | 2001-09-22 |
Family
ID=22612589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2000001289A PE20010962A1 (es) | 1999-12-03 | 2000-12-01 | Derivados de heterociclo-alquilsulfonil-pirazol como agentes anti-inflamatorios/analgesicos |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US6531492B1 (es) |
| EP (1) | EP1233959B1 (es) |
| JP (1) | JP2003517475A (es) |
| KR (1) | KR20020058074A (es) |
| CN (1) | CN1423646A (es) |
| AP (1) | AP2002002532A0 (es) |
| AR (1) | AR026711A1 (es) |
| AT (1) | ATE291019T1 (es) |
| AU (1) | AU783359B2 (es) |
| BG (1) | BG106694A (es) |
| BR (1) | BR0016031A (es) |
| CA (1) | CA2392931A1 (es) |
| CO (1) | CO5261496A1 (es) |
| DE (1) | DE60018792T2 (es) |
| DZ (1) | DZ3246A1 (es) |
| EA (1) | EA200200520A1 (es) |
| ES (1) | ES2238324T3 (es) |
| GT (1) | GT200000204A (es) |
| HK (1) | HK1052701A1 (es) |
| HU (1) | HUP0300157A3 (es) |
| IL (1) | IL149581A0 (es) |
| IS (1) | IS6376A (es) |
| MA (1) | MA26848A1 (es) |
| MX (1) | MXPA02005539A (es) |
| NO (1) | NO20022624L (es) |
| OA (1) | OA12100A (es) |
| PA (1) | PA8508201A1 (es) |
| PE (1) | PE20010962A1 (es) |
| PL (1) | PL356669A1 (es) |
| SK (1) | SK7412002A3 (es) |
| TN (1) | TNSN00235A1 (es) |
| WO (1) | WO2001040216A1 (es) |
| YU (1) | YU35102A (es) |
| ZA (1) | ZA200204285B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6833373B1 (en) | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| US6858598B1 (en) | 1998-12-23 | 2005-02-22 | G. D. Searle & Co. | Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| US20040248945A1 (en) * | 1999-04-23 | 2004-12-09 | Smithkline Beecham P.L.C. | Thiazolidinedione derivative and its use as antidiabetic |
| HK1052701A1 (zh) * | 1999-12-03 | 2003-09-26 | 辉瑞产品公司 | 作为抗炎/镇痛剂的杂环-烷基磺酰基吡唑衍生物 |
| DE60204823T2 (de) * | 2001-07-05 | 2005-12-29 | Pfizer Products Inc., Groton | Heterocyclo-alkylsulfonyl Pyrazole als entzündungshemmende/analgetische Mittel |
| DE10135027A1 (de) * | 2001-07-18 | 2003-02-06 | Solvay Pharm Gmbh | Verwendung Trifluoracetylalkyl-substituierter Phenyl-, Phenol- und Benzoylderivate in der Behandlung und/oder Prophylaxe von Obestias und deren Begleit- und/oder Folgeerkrankungen |
| US20040248950A1 (en) * | 2001-08-24 | 2004-12-09 | Natsuki Ishizuka | Apo ai expression accelerating agent |
| YU67702A (sh) * | 2001-09-28 | 2004-12-31 | Pfizer Products Inc. | Postupak za dobijanje alkansulfonil piridina |
| GT200200183A (es) | 2001-09-28 | 2003-05-23 | Procedimiento para preparar derivados de heterocicloalquilsulfonil pirazol | |
| PT1441714E (pt) * | 2001-10-25 | 2008-03-10 | Novartis Ag | Combinações compreendendo um inibidor selectivo da ciclo-oxigenase 2 |
| WO2003037330A1 (en) * | 2001-11-02 | 2003-05-08 | Pfizer Products Inc. | Sulfonyl-and sulfonylheteroaryl-pyrazoles with a hydrazinyl or nitrogen oxide substituent at the 5-position for use as cyclooxygenase inhibitors |
| WO2003037351A1 (en) * | 2001-11-02 | 2003-05-08 | Pfizer Products Inc. | Heterocyclo-alkylsulfonyl pyrazoles and their use as cox-2 inhibitors |
| WO2003037335A1 (en) * | 2001-11-02 | 2003-05-08 | Pfizer Products Inc. | 5-heteroatom-substituted pyrazoles |
| WO2003037352A1 (en) * | 2001-11-02 | 2003-05-08 | Pfizer Products Inc. | 1-phenyl-5-n-heterocyclyl-pyrazoles as cyclooxygenase inhibitors for the treatment of inflammation associated disorders |
| BR0213763A (pt) | 2001-11-02 | 2004-10-19 | Pfizer Prod Inc | Sìntese eficiente de pirazóis contendo um heteroátomo -5 |
| KR100686537B1 (ko) * | 2001-12-28 | 2007-02-27 | 씨제이 주식회사 | 사이클로옥시게나제-2 의 저해제로서 선택성이 뛰어난디아릴 1,2,4-트리아졸 유도체 |
| TW200403072A (en) * | 2002-01-23 | 2004-03-01 | Upjohn Co | Combination therapy for the treatment of bacterial infections |
| KR100470076B1 (ko) * | 2002-11-27 | 2005-02-05 | 씨제이 주식회사 | 1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물 |
| US7247628B2 (en) * | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| US7622471B2 (en) | 2003-02-07 | 2009-11-24 | Daiichi Pharmaceutical Co., Ltd. | Pyrazole derivatives having a pyridazine and pyridine functionality |
| RU2379292C2 (ru) * | 2003-04-18 | 2010-01-20 | Мемори Фармасьютиклз Корпорейшн | Производные пиразола в качестве ингибиторов фосфодиэстеразы 4 |
| US20050107350A1 (en) * | 2003-08-22 | 2005-05-19 | Pharmacia Corporation | Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith |
| CN101166733A (zh) | 2004-10-15 | 2008-04-23 | 记忆药物公司 | 作为磷酸二酯酶4抑制剂的吡唑衍生物 |
| CN109438365B (zh) * | 2018-12-06 | 2022-04-05 | 华南师范大学 | N-(3-((4-三氟甲基)-2-嘧啶基)氨基苯基)-2,6-二氟苯磺酰胺衍生物 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH27357A (en) * | 1989-09-22 | 1993-06-21 | Fujisawa Pharmaceutical Co | Pyrazole derivatives and pharmaceutical compositions comprising the same |
| IL104311A (en) | 1992-02-05 | 1997-07-13 | Fujisawa Pharmaceutical Co | Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
| US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
| US5434178A (en) | 1993-11-30 | 1995-07-18 | G.D. Searle & Co. | 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation |
| US5475018A (en) | 1993-11-30 | 1995-12-12 | G. D. Searle & Co. | 1,5-diphenyl pyrazole compounds for treatment of inflammation |
| ATE233245T1 (de) | 1993-11-30 | 2003-03-15 | Searle & Co | Substituierte pyrazolyl-benzolsulfonamide und ihre verwendung als cyclooxygenaseii inhibitoren |
| US5401765A (en) | 1993-11-30 | 1995-03-28 | G. D. Searle | 1,4,5-triphenyl pyrazolyl compounds for the treatment of inflammation and inflammation-related disorders |
| JPH10504542A (ja) | 1994-07-27 | 1998-05-06 | ジー．ディー．サール アンド カンパニー | 炎症処置用の置換チアゾール化合物 |
| US5620999A (en) | 1994-07-28 | 1997-04-15 | Weier; Richard M. | Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation |
| US5585504A (en) | 1994-09-16 | 1996-12-17 | Merck & Co., Inc. | Process of making cox-2 inhibitors having a lactone bridge |
| EP0799218B1 (en) | 1994-12-21 | 2003-02-19 | Merck Frosst Canada & Co. | Diaryl-2-(5h)-furanones as cox-2 inhibitors |
| US5691374A (en) | 1995-05-18 | 1997-11-25 | Merck Frosst Canada Inc. | Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors |
| WO1997011074A1 (en) * | 1995-09-22 | 1997-03-27 | Fujisawa Pharmaceutical Co., Ltd. | Novel processes for producing pyridoindole derivatives |
| US5756529A (en) * | 1995-09-29 | 1998-05-26 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies |
| GB9520584D0 (en) | 1995-10-09 | 1995-12-13 | Fujisawa Pharmaceutical Co | Pyrazole derivatives,processes for preparation thereof and pharmaceutical composition comprising the same |
| UA57002C2 (uk) | 1995-10-13 | 2003-06-16 | Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. | Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування |
| EP0904269B1 (en) | 1995-10-30 | 2002-01-23 | Merck Frosst Canada & Co. | 3,4-diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors |
| HK1052701A1 (zh) * | 1999-12-03 | 2003-09-26 | 辉瑞产品公司 | 作为抗炎/镇痛剂的杂环-烷基磺酰基吡唑衍生物 |
-
2000
- 2000-11-24 HK HK03104988.3A patent/HK1052701A1/zh unknown
- 2000-11-24 DE DE60018792T patent/DE60018792T2/de not_active Expired - Fee Related
- 2000-11-24 DZ DZ003246A patent/DZ3246A1/fr active
- 2000-11-24 AT AT00974741T patent/ATE291019T1/de not_active IP Right Cessation
- 2000-11-24 EA EA200200520A patent/EA200200520A1/ru unknown
- 2000-11-24 WO PCT/IB2000/001748 patent/WO2001040216A1/en not_active Ceased
- 2000-11-24 IL IL14958100A patent/IL149581A0/xx unknown
- 2000-11-24 CN CN00818329A patent/CN1423646A/zh active Pending
- 2000-11-24 YU YU35102A patent/YU35102A/sh unknown
- 2000-11-24 HU HU0300157A patent/HUP0300157A3/hu unknown
- 2000-11-24 EP EP00974741A patent/EP1233959B1/en not_active Expired - Lifetime
- 2000-11-24 MX MXPA02005539A patent/MXPA02005539A/es unknown
- 2000-11-24 SK SK741-2002A patent/SK7412002A3/sk unknown
- 2000-11-24 CA CA002392931A patent/CA2392931A1/en not_active Abandoned
- 2000-11-24 KR KR1020027007082A patent/KR20020058074A/ko not_active Ceased
- 2000-11-24 AU AU12953/01A patent/AU783359B2/en not_active Ceased
- 2000-11-24 OA OA1200200159A patent/OA12100A/en unknown
- 2000-11-24 AP APAP/P/2002/002532A patent/AP2002002532A0/en unknown
- 2000-11-24 PL PL00356669A patent/PL356669A1/xx not_active Application Discontinuation
- 2000-11-24 BR BR0016031-8A patent/BR0016031A/pt not_active IP Right Cessation
- 2000-11-24 ES ES00974741T patent/ES2238324T3/es not_active Expired - Lifetime
- 2000-11-24 JP JP2001541900A patent/JP2003517475A/ja active Pending
- 2000-11-28 US US09/724,446 patent/US6531492B1/en not_active Expired - Fee Related
- 2000-12-01 TN TNTNSN00235A patent/TNSN00235A1/fr unknown
- 2000-12-01 PE PE2000001289A patent/PE20010962A1/es not_active Application Discontinuation
- 2000-12-04 CO CO00092095A patent/CO5261496A1/es not_active Application Discontinuation
- 2000-12-04 GT GT200000204A patent/GT200000204A/es unknown
- 2000-12-04 AR ARP000106402A patent/AR026711A1/es unknown
- 2000-12-04 PA PA20008508201A patent/PA8508201A1/es unknown
-
2002
- 2002-05-10 IS IS6376A patent/IS6376A/is unknown
- 2002-05-13 BG BG106694A patent/BG106694A/xx unknown
- 2002-05-29 ZA ZA200204285A patent/ZA200204285B/en unknown
- 2002-05-31 MA MA26662A patent/MA26848A1/fr unknown
- 2002-06-03 NO NO20022624A patent/NO20022624L/no unknown
-
2003
- 2003-01-14 US US10/342,666 patent/US20030236258A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20010962A1 (es) | Derivados de heterociclo-alquilsulfonil-pirazol como agentes anti-inflamatorios/analgesicos | |
| ES2187675T3 (es) | (metilsulfonil)fenil-2-(5h)-furanonas como inhibidores de cox-2. | |
| PE133999A1 (es) | Derivados de acido hidroxamico como inhibidores de metaloproteasas de matriz (mmp) | |
| ES2115237T3 (es) | Fenil heterociclos como inhibidores de la ciclooxigenasa-2. | |
| PE20011164A1 (es) | Derivados de eteres de pirazol como agentes antiinflamatorios / analgesicos | |
| MA31419B1 (fr) | Derives de pyridine | |
| ES2139943T3 (es) | Nuevos inhibidores de la sintasa de prostaglandina. | |
| BR0002515A (pt) | Derivados de 4-arilpiperidina para o tratamento do prurido | |
| PE55097A1 (es) | Isotiazolonas | |
| PE20050012A1 (es) | Compuestos de benzopirano como inhibidores de la ciclooxigenasa-2 | |
| BR0002518A (pt) | Derivados de 4-arilpiperidina para o tratamento de prurido | |
| ECSP045078A (es) | Tiofen- y tiazolsulfonamidas como agentes antineoplásicos | |
| SE8106125L (sv) | 4,5-polymetylen-4-isotiazolin-3-oner, sett for framstellning derav och anvendning derav som baktericida och fungicida medel | |
| PE20040907A1 (es) | Derivados de anilinopirazol | |
| DK0903347T3 (da) | Hidtil ukendte cyclodepsipeptid PF1022-derivater | |
| AR035756A1 (es) | Uso de carbamatos en la preparacion de medicamentos para la prevencion o tratamiento de trastornos neurodegenerativos | |
| PE20040768A1 (es) | Derivados de arilen-(2-amino-fenil)-carboxamida como inhibidores de la histona desacetilasa (hdac) | |
| ATE453389T1 (de) | Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen | |
| ATE243209T1 (de) | Tetrahydro gamma-carboline | |
| DE69931051D1 (de) | Neue vinylbenzolderivate | |
| PE20020905A1 (es) | Derivados de alcoxicarbonilaminotetrazolil fenilo o acido alcoxicarbonilamino benzoico como antagonistas ip | |
| PE20050254A1 (es) | N-[3-(3-SUSTITUIDAS-PIRAZOLO [1,5-a]PIRIMIDIN-7-IL) FENIL]-SULFONAMIDAS Y COMPOSICIONES RELACIONADAS | |
| ES2152648T3 (es) | Difenilestilbenos como profarmacos inhibidores de la cox-2. | |
| DK1562604T3 (da) | Prostaglandinforbindelser til behandling af fedme | |
| BR0313000A (pt) | Compostos, composição farmacêutica e método para efetuar a inibição da enzima pde4, realçar a cognição e/ou tratar a psicose em um paciente |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |